XBIO - Xenetic Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

XBIO

XENETIC BIOSCIENCES, INC.

NASDAQ

$3.98

▲ UP 0.25% (0.01)

KEY STATISTICS

Market Cap$9.12 M

52w High$13.93

52w Low$1.90

Dividend Yield—

Frequency—

P/E-3.32

Volume19.58K

Shares Out.2.29M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James F. Parslow

COMPENSATION 2026

Salary$367,500

Stock Awards$0

Incentive Plan Pay$119,438

All Other Comp.$29,241

Total$750,231

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 30, 2016

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 6, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2023-05-15	Reverse	1:10
2019-06-25	Reverse	1:12
2016-06-06	Reverse	1:33

PRICE

$3.98 ▲ UP 0.25% (+$0.01)

OVERLAYS

About Xenetic Biosciences, Inc.

https://www.xeneticbio.com ↗

Xenetic Biosciences develops personalized CAR T therapies targeting tumor neoantigens, B-cell lymphomas, and leverages its PolyXen platform through collaborations with major biotech partners.

INDUSTRY

Biotechnology

A PRODUCT XENETIC BIOSCIENCES, INC. IS KNOWN FOR

DNase-Based Oncology Platform

Xenetic's therapeutic platform aims to enhance cancer treatments by targeting and breaking down NETs involved in tumor progression, advancing toward clinical trials as an adjunct for solid tumors like pancreatic and colorectal cancer.